litlas
Log inCreate account

Ramesh K. Ramanathan

Active 1999–2024

73
Papers
26,367
Citations
68
h-index
72
i10-index

Citations

Citations per year for Ramesh K. Ramanathan2000: 3 citations2001: 11 citations2002: 25 citations2003: 41 citations2004: 69 citations2005: 104 citations2006: 116 citations2007: 154 citations2008: 148 citations2009: 166 citations2010: 118 citations2011: 132 citations2012: 154 citations2013: 172 citations2014: 191 citations2015: 250 citations2016: 239 citations2017: 253 citations2018: 284 citations2019: 988 citations2020: 1,141 citations2021: 1,011 citations2022: 758 citations2023: 499 citations2024: 729 citations2025: 321 citations2026: 12 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,192 citing papers, 28.9% of this breakdownChina: 1,212 citing papers, 11% of this breakdownItaly: 622 citing papers, 5.6% of this breakdownUnited Kingdom: 606 citing papers, 5.5% of this breakdownGermany: 580 citing papers, 5.2% of this breakdownJapan: 516 citing papers, 4.7% of this breakdownFrance: 457 citing papers, 4.1% of this breakdownSpain: 352 citing papers, 3.2% of this breakdownNetherlands: 315 citing papers, 2.8% of this breakdownCanada: 304 citing papers, 2.8% of this breakdownAustralia: 275 citing papers, 2.5% of this breakdownSouth Korea: 258 citing papers, 2.3% of this breakdown
0%28.9%Other 21.4%

Institutions

Fields

  • Medicine68.1%
  • Biochemistry, Genetics and Molecular Biology19.5%
  • Immunology and Microbiology4.3%
  • Materials Science3.6%
  • Engineering1.6%
  • Neuroscience0.7%
  • Other2.2%

Topics

  • Pancreatic and Hepatic Oncology Research10.7%
  • Colorectal Cancer Treatments and Studies3.6%
  • Cholangiocarcinoma and Gallbladder Cancer Studies3.5%
  • Cancer Genomics and Diagnostics2.8%
  • Cancer Immunotherapy and Biomarkers2.6%
  • Cancer Cells and Metastasis2.5%
  • Other74.3%

Coauthors

All papers

Open in search
  1. Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

    Authors: Daniel D. Von Hoff, Thomas J. Ervin, Francis P. Arena, E. Gabriela Chiorean, Jeffrey R. Infante, Malcolm J. Moore, Thomas E. Seay, Sergei Tjulandin, Wen Wee, Mansoor N. Saleh, Marion Harris, Michele Reni, Scot Dowden, Daniel A. Laheru, Nathan Bahary, Ramesh K. Ramanathan, Josep Tabernero, Manuel Hidalgo, David Goldstein, Eric Van Cutsem, Xinyu Wei, José Iglesias, Markus F. Renschler - New England Journal of Medicine 2013 cited by 6,661

  2. Hepatocytes direct the formation of a pro-metastatic niche in the liver

    Authors: Jae W. Lee, Meredith L. Stone, Paige M. Porrett, Stacy K. Thomas, Chad A. Komar, Joey H. Li, Devora Delman, Kathleen Graham, Whitney L. Gladney, Xia Hua, Taylor A. Black, Austin L. Chien, Krishna S. Majmundar, Jeffrey C. Thompson, Stephanie S. Yee, Mark H. O’Hara, Charu Aggarwal, Dong Xin, Abraham Shaked, Mingming Gao, Dexi Liu, Mitesh J. Borad, Ramesh K. Ramanathan, Erica L. Carpenter, Ailing Ji, Maria C. de Beer, Frederick C. de Beer, Nancy R. Webb, Gregory L. Beatty - Nature 2019 cited by 423

  3. Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor

    Authors: William D. Tap, Zev A. Wainberg, Stephen P. Anthony, Prabha N. Ibrahim, Chao Zhang, John H. Healey, Bartosz Chmielowski, Arthur P. Staddon, Allen Lee Cohn, Geoffrey I. Shapiro, Vicki L. Keedy, Arun S. Singh, Igor Puzanov, Eunice L. Kwak, Andrew J. Wagner, Daniel D. Von Hoff, Glen J. Weiss, Ramesh K. Ramanathan, Jiazhong Zhang, Gaston Habets, Ying Zhang, Elizabeth A. Burton, Gary C. Visor, Laura Sanftner, Paul Severson, Hoa Nguyen, Marie J. Kim, Adhirai Marimuthu, Garson Tsang, Rafe Shellooe, C. M. Gee, Brian L. West, Peter Hirth, K. B. Nolop, Matt van de Rijn, Henry H. Hsu, Charles Peterfy, Paul Lin, Sandra Tong-Starksen, Gideon Bollag - New England Journal of Medicine 2015 cited by 582

  4. Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma

    Authors: Milind Javle, Maeve A. Lowery, Rachna T. Shroff, Karl Heinz Weiss, Christoph Springfeld, Mitesh J. Borad, Ramesh K. Ramanathan, Lipika Goyal, Saeed Sadeghi, Teresa Macarulla, Anthony B. El-Khoueiry, Robin Kate Kelley, Ivan Borbath, Su Pin Choo, Do‐Youn Oh, Philip A. Philip, Li‐Tzong Chen, Thanyanan Reungwetwattana, Eric Van Cutsem, Kun‐Huei Yeh, Kristen K. Ciombor, Richard S. Finn, Anuradha Patel, Suman Sen, Dale Porter, Randi Isaacs, Andrew X. Zhu, Ghassan K. Abou‐Alfa, Tanios Bekaii‐Saab - Journal of Clinical Oncology 2017 cited by 715

  5. Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313

    Authors: Ramesh K. Ramanathan, Shannon McDonough, Philip A. Philip, Sunil R. Hingorani, Jill Lacy, Jeremy Kortmansky, Jaykumar Thumar, E. Gabriela Chiorean, Anthony F. Shields, Deepti Behl, Paul Mehan, Rakesh Gaur, Tara Elisabeth Seery, Katherine A. Guthrie, Howard S. Höchster - Journal of Clinical Oncology 2019 cited by 323

  6. Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers

    Authors: Rachna T. Shroff, Milind Javle, Lianchun Xiao, Ahmed O. Kaseb, Gauri R. Varadhachary, Robert A. Wolff, Kanwal Raghav, Michiko Iwasaki, Peter Masci, Ramesh K. Ramanathan, Daniel H. Ahn, Tanios Bekaii‐Saab, Mitesh J. Borad - JAMA Oncology 2019 cited by 473

  7. Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma

    Authors: Ana De Jesus‐Acosta, Elizabeth A. Sugar, Peter J. O’Dwyer, Ramesh K. Ramanathan, Daniel D. Von Hoff, Zeshaan A. Rasheed, Lei Zheng, Asma Begum, Robert A. Anders, Anirban Maitra, Florencia McAllister, N.V. Rajeshkumar, Shinichi Yabuuchi, Roeland F. de Wilde, Bhavina Batukbhai, İsmet Şahin, Daniel A. Laheru - British Journal of Cancer 2019 cited by 170

  8. Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial

    Authors: Daniel D. Von Hoff, Ramesh K. Ramanathan, Mitesh J. Borad, Daniel A. Laheru, Lon Smith, Tina E. Wood, Ronald L. Korn, Neil Desai, Vuong Trieu, J. L. Mesías Iglesias, Hui Zhang, Patrick Soon‐Shiong, Tao Shi, N.V. Rajeshkumar, Anirban Maitra, Manuel Hidalgo - Journal of Clinical Oncology 2011 cited by 1,045

  9. Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers

    Authors: Johann S. de Bono, Ramesh K. Ramanathan, Lida A. Mina, Rashmi Chugh, John A. Glaspy, Saeed Rafii, Stan B. Kaye, Jasgit C. Sachdev, John V. Heymach, David C. Smith, Joshua W. Henshaw, Ashleigh Herriott, Miranda Patterson, Nicola J. Curtin, Lauren A. Byers, Zev A. Wainberg - Cancer Discovery 2017 cited by 383

  10. Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors

    Authors: Daniel D. Von Hoff, Monica Mita, Ramesh K. Ramanathan, Glen J. Weiss, Alain C. Mita, Patricia LoRusso, Howard A. Burris, Lowell L. Hart, Susan C. Low, Donald M. Parsons, Stephen E. Zale, Jason M. Summa, Hagop Youssoufian, Jasgit C. Sachdev - Clinical Cancer Research 2016 cited by 272

  11. Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial

    Authors: Patrick J. Loehrer, Yang Feng, Higinia R. Cárdenes, Lynne I. Wagner, Joanna M. Brell, David Cella, Patrick J. Flynn, Ramesh K. Ramanathan, Christopher H. Crane, Steven R. Alberts, Al B. Benson - Journal of Clinical Oncology 2011 cited by 832

  12. First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors

    Authors: John H. Strickler, Colin D. Weekes, John Nemunaitis, Ramesh K. Ramanathan, Rebecca S. Heist, Daniel Morgensztern, Eric Angevin, Todd M. Bauer, Huibin Yue, Monica Motwani, Apurvasena Parikh, Edward B. Reilly, Daniel Afar, Louie Naumovski, Karen Kelly - Journal of Clinical Oncology 2018 cited by 139

  13. Oxaliplatin Combined With Weekly Bolus Fluorouracil and Leucovorin As Surgical Adjuvant Chemotherapy for Stage II and III Colon Cancer: Results From NSABP C-07

    Authors: J. Philip Kuebler, H. Samuel Wieand, Michael J. O’Connell, Roy E. Smith, Linda H. Colangelo, Greg Yothers, Nicholas J. Petrelli, Michael Findlay, Thomas E. Seay, James N. Atkins, John L. Zapas, J. Wendall Goodwin, Louis Fehrenbacher, Ramesh K. Ramanathan, Barbara A. Conley, Patrick J. Flynn, Gamini S. Soori, Lauren K. Colman, Edward A. Levine, Keith S. Lanier, Norman Wolmark - Journal of Clinical Oncology 2007 cited by 1,053

  14. First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas

    Authors: Amita Patnaik, Leonard J. Appleman, Anthony W. Tolcher, Kyriakos P. Papadopoulos, Muralidhar Beeram, Drew Rasco, Glen J. Weiss, Jasgit C. Sachdev, Manpreet Chadha, Maddie Fulk, Samuel Ejadi, James M. Mountz, Michael T. Lotze, Frederico G. S. Toledo, Edward Chu, Michael Jeffers, Carol E. Peña, Chenjing Xia, Stefanie Reif, Isabelle Genvresse, Ramesh K. Ramanathan - Annals of Oncology 2016 cited by 236

  15. Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors

    Authors: Stergios J. Moschos, Ryan J. Sullivan, Wen-Jen Hwu, Ramesh K. Ramanathan, Alex A. Adjei, Peter C.C. Fong, Ronnie Shapira‐Frommer, Hussein Tawbi, Joseph Rubino, Thomas S. Rush, Da Zhang, Nathan R. Miselis, Ahmed A. Samatar, Patrick Chun, Eric H. Rubin, James E. Schiller, Brian J. Long, Priya Dayananth, Donna Carr, Paul T. Kirschmeier, W. Robert Bishop, Yongqi Deng, Alan Cooper, Gerald W. Shipps, Blanca Homet Moreno, Lídia Robert, Antoni Ribas, Keith T. Flaherty - JCI Insight 2018 cited by 147

  16. Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours

    Authors: Devalingam Mahalingam, Manish R. Patel, Jasgit C. Sachdev, Lowell L. Hart, Niels Halama, Ramesh K. Ramanathan, John Sarantopoulos, Dirk Völkel, Ashraf Youssef, Floris A. de Jong, Apostolia M. Tsimberidou - British Journal of Clinical Pharmacology 2020 cited by 79

  17. Safety and activity of IT-139, a ruthenium-based compound, in patients with advanced solid tumours: a first-in-human, open-label, dose-escalation phase I study with expansion cohort

    Authors: Howard A. Burris, Suzanne J. Bakewell, Johanna C. Bendell, Jeffrey R. Infante, Suzanne F. Jones, David R. Spigel, Glen J. Weiss, Ramesh K. Ramanathan, Angela Ogden, Daniel D. Von Hoff - ESMO Open 2016 cited by 152

  18. First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies

    Authors: Glen J. Weiss, Joseph Chao, Jeffrey D. Neidhart, Ramesh K. Ramanathan, Dawn Bassett, James A. Neidhart, Chung Hang Jonathan Choi, Warren Chow, Vincent Chung, Stephen J. Forman, Edward G. Garmey, Jungyeon Hwang, D. Lynn Kalinoski, Marianna Koczywas, Jeff Longmate, Roger J. Melton, Robert J. Morgan, J C Oliver, Joanna Peterkin, John L. Ryan, Thomas Schluep, Timothy W. Synold, Przemyslaw Twardowski, Mark E. Davis, Yun Yen - Investigational New Drugs 2013 cited by 220

  19. A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer

    Authors: Richard M. Goldberg, Daniel J. Sargent, Roscoe F. Morton, Charles S. Fuchs, Ramesh K. Ramanathan, Stephen K. Williamson, B. Findlay, Henry C. Pitot, Steven R. Alberts - Journal of Clinical Oncology 2003 cited by 2,268

  20. Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study

    Authors: Ramesh K. Ramanathan, Ronald L. Korn, Natarajan Raghunand, Jasgit C. Sachdev, Ronald G. Newbold, Gayle Jameson, Gerald J. Fetterly, Joshua Prey, Stephan G. Klinz, Jaeyeon Kim, Jason E. Cain, Bart S. Hendriks, Daryl C. Drummond, Eliel Bayever, Jonathan B. Fitzgerald - Clinical Cancer Research 2017 cited by 172

  21. A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination

    Authors: Ramesh K. Ramanathan, James L. Abbruzzese, Tomislav Dragovich, Lynn Kirkpatrick, Jose Guillen, Amanda F. Baker, Linda Pestano, Sylvan Green, Daniel D. Von Hoff - Cancer Chemotherapy and Pharmacology 2010 cited by 119

  22. Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline

    Authors: Davendra Sohal, Pamela B. Mangu, Alok A. Khorana, Manish A. Shah, Philip A. Philip, Eileen M. O’Reilly, Hope E. Uronis, Ramesh K. Ramanathan, Christopher H. Crane, Anitra Engebretson, Joseph T. Ruggiero, Mehmet Sitki Copur, Michelle Lau, Susan G. Urba, Daniel A. Laheru - Journal of Clinical Oncology 2016 cited by 353

  23. Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer

    Authors: Ramesh K. Ramanathan, Kenneth Lee, John McKolanis, Elizabeth Hitbold, Wolfgang H. Schraut, A. James Moser, Elizabeth Warnick, Theresa L. Whiteside, Jennifer Osborne, Hyoung Kim, Roger Day, Monica Troetschel, Olivera J. Finn - Cancer Immunology Immunotherapy 2004 cited by 219

  24. Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors

    Authors: Dejan Juric, Ian E. Krop, Ramesh K. Ramanathan, Timothy R. Wilson, Joseph A. Ware, Sandra Sanabria Bohórquez, Heidi Savage, Deepak Sampath, Laurent Salphati, Ray Lin, Huan Jin, Hema Parmar, Jerry Y. Hsu, Daniel D. Von Hoff, José Baselga - Cancer Discovery 2017 cited by 160